Ongoing Disclosure Notices - Options, PSRs, Ordinary Shares

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
18 September 2025
Date of last disclosure:
5 September 2025
Director or senior manager giving disclosure
Full name(s):
Justin Peter Callahan
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Vice President - Sales & Marketing
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
a) Options to acquire Ordinary Shares
b) Performance Share Rights
c) Ordinary Shares
Nature of the affected relevant interest(s):
Beneficial Interest
For that relevant interest-
Number held in class before acquisition or disposal:
a) 135,110 Options to acquire Ordinary Shares
b) 77,819 Performance Share Rights
c) 213,210 Ordinary Shares (note: this comprises
168,371 Ordinary Shares disclosed in the last
disclosure made on 5 September 2025 + 44,839
Ordinary Shares held by Mr Callahan since prior to
his appointment as Vice President - Sales &
Marketing on 1 April 2024 (disclosure of which had
previously been inadvertently omitted))
Number held in class after acquisition or disposal:
a) 103,960 Options to acquire Ordinary Shares
b) 64,091 Performance Share Rights
c) 220,467 Ordinary Shares
Current registered holder(s):
Justin Peter Callahan
Registered holder(s) once transfers are registered:
Justin Peter Callahan
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
Four
Details of transactions requiring disclosure-

Date of transaction:
a) 12 September 2025
b) 12 September 2025
c) 16 September 2025
d) 17 September 2025
Nature of transaction:
a) Exercise and cancellation of Options and Issue
of Ordinary Shares
b) Exercise of Performance Share Rights and
Issue of Ordinary Shares
c) Sale of Ordinary Shares
d) Sale of Ordinary Shares
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be readily by
converted into a cash value, describe the consideration:
a) Exercise price of $19.63 per Ordinary Share
b) Nil
c) $37.60 per Ordinary Share
d) $37.09 per Ordinary Share
Number of financial products to which the transaction related:
a) Exercise of 31,150 Options and Issue of 15,107
Ordinary Shares
b) Exercise of 13,728 Performance Share Rights
and Issue of 13,728 Ordinary Shares
c) Sale of 13,728 Ordinary Shares
d) Sale of 7,850 Ordinary Shares
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
18 September 2025
Name and title of authorised person:
Raelene Leonard,
General Counsel & Company Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
18 September 2025
Date of last disclosure:
16 September 2025
Director or senior manager giving disclosure
Full name(s):
Lyndal Jane York
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Chief Financial Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary Shares
Nature of the affected relevant interest(s):
Beneficial interest
For that relevant interest-
Number held in class before acquisition or disposal:
80,617 Ordinary Shares
Number held in class after acquisition or disposal:
79,117 Ordinary Shares
Current registered holder(s):Lyndal Jane York and Alexander Eric York
Registered holder(s) once transfers are registered:Lyndal Jane York and Alexander Eric York
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
One
Details of transactions requiring disclosure-
Date of transaction:
12 September 2025
Nature of transaction:
Sale of Ordinary Shares
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be readily by
converted into a cash value, describe the consideration:
$38.0986 per Ordinary Share

Number of financial products to which the transaction related:
Sale of 1,500 Ordinary Shares
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
a) Options to acquire Ordinary Shares
b) Performance Share Rights
Nature of relevant interest:
Beneficial Interest
For that relevant interest,-
Number held in class:
a) 122,638 Options to acquire Ordinary Shares
b) 74,216 Performance Share Rights
Current registered holder(s):
Lyndal Jane York
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
18 September 2025
Name and title of authorised person:
Raelene Leonard,
General Counsel & Company Secretary